Lexeo Therapeutics is a clinical stage genetic medicine company engaged in transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Co.'s primary cardiovascular product candidate, LX2006, for the treatment of patients with Friedreich's ataxia cardiomyopathy. Co.'s second cardiovascular product candidate, LX2020, for the treatment of arrhythmogenic cardiomyopathy. Co.'s main Alzheimer's disease product candidate, LX1001, for the treatment of APOE4 homozygous patients with Alzheimer's disease. The LXEO average annual return since 2023 is shown above.
The Average Annual Return on the LXEO average annual return since 2023 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether LXEO average annual return since 2023 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the LXEO average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|